1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

  • October 2019
  • 128 pages
  • ID: 5827504
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

Summary
Axial spondyloarthritis (axSpA) is a disease group encompassing both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).These conditions are chronic, autoinflammatory disorders of the sacroiliac joints and spine, an area also known as the axial skeleton.

The disease is typically diagnosed in young adulthood to middle age (16-45 years) and has a seven- to nine-year delay of diagnosis.The axSpA market has historically been reliant on anti-tumor necrosis factor (TNF) therapies that have been available for over a decade, and the pipeline for drugs in late-stage development was lacking, but recent developments have led to research on novel treatment mechanisms.

This will be vital in treating the underdiagnosed nr-axSpA population.

In January 2016, Novartis gained approval for Cosentyx (secukinumab), the first-in-class interleukin (IL)-17 inhibitor that was the first new biologic treatment approved for AS that was not an anti-TNF.Moreover, biosimilars of currently marketed anti-TNF biologics recently entered the market, with Remicade (infliximab) biosimilars first marketed in 2015 in Europe.

This is likely to result in a highly competitive market for patients who have failed multiple non-steroidal anti-inflammatory drugs (NSAIDs).Competition will intensify with the arrival of new anti-IL-17 treatments and a new class of therapies in development, Janus kinase (JAK) inhibitors, which will offer a more convenient form of administration.

With existing unmet need for all patients, particularly nr-axSpA patients, being diagnosed in a timely manner and having treatment options that are not solely subcutaneously or intravenously administered, axSpA represents an increasingly important rheumatology sector for drug developers.

The analyst estimates that sales of drugs in the axSpA market were approximately $3.1B in 2018 in the 7MM. The US was the largest market, with approximately $2.3B in drug sales, which represented 75.3% of the total axSpA market. The 5EU market contributed $705M in sales and Japan contributed sales of $54M in 2018.

Global sales in the axSpA market are expected to grow to $3.6B by 2028, at a Compound Annual Growth Rate (CAGR) of 1.5% from 2018-2028. The analyst forecasts the US to grow to $2.7B (74.7% of global sales), the 5EU to grow to $850M (23.9% of global sales), and Japan to shrink to $52M (1.5% of global sales) over the next 10 years.

Key Questions Answered
Over the forecast period, the axSpA market will see the entry of pipeline agents such as the interleukin 17 inhibitors and the JAK inhibitors, the sales of which will offset the loss of sales caused by the entry of biosimilars.How do products compete against each other? Which of these drugs will have the highest peak sales, and why?
Key Opinion Leaders (KOLs) interviewed have indicated that there are several unmet needs within the axSpA indication.

What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
The axSpA market is likely to become a turbulent space throughout the forecast period and beyond.Which companies are set to be major players in axSpA during the forecast period?

Key Highlights
The greatest driver of growth in the global axSpA market will be the launches of five pipeline therapies during the forecast period.

The entry of these anticipated therapies, including Eli Lilly’s Taltz and Pfizer’s tofacitinib, will be subject to moderate uptake among the AS and nr-axSpA populations.

The main barrier to growth in the axSpA market will be the patent expiry, and subsequent launch of biosimilars of Humira (adalimumab) in the US, and the genericization of tofacitinib in the latter half of the forecast across the 7MM.

The most important unmet needs in axSpA are the need for speedier diagnosis and convincing patients to start biologic therapy.The former is being addressed by the increasingly routine use of MRI instead of X-ray to diagnose patients, and the greater understanding and awareness of nr-axSpA.

The latter is impacted by poor patient education about their disease and a fear of subcutaneous/intravenous injection.

Factors driving a low biologic therapy treatment rate include some negative or fearful attitudes towards subcutaneously/intravenously administered therapeutics, nr-axSpA patients not perceiving themselves as severe enough to warrant biologic treatment, and a high ACOT for some biologic therapies currently on the market and in late-stage development.

Scope
- Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global axSpA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global axSpA therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global axSpA therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019SummaryInterleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded ...

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2019

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2019SummaryVascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is ...

Axial Spondyloarthritis - Pipeline Review, H2 2019

Axial Spondyloarthritis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Axial Spondyloarthritis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2019, provides an overview of the ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on